1. Hartog N.L, Wu E.Y, Rider N.L, Meng Y, Hartline B, Adams P, Aggarwal S, Harrington A. Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome. Clinical and Experimental Medicine. 2025;25(1):246. http://dx.doi.org/10.1007/s10238-025-01773-1

2. Aggarwal S, Serbin M, Bron M. CO113 Indirect Treatment Comparison for Early Efficacy of VMAT2 Inhibitors for Tardive Dyskinesia and Chorea Associated with Huntington's Disease. Value in Health. 2025;28(6):S43. http://dx.doi.org/10.1016/j.jval.2025.04.198

3. Aggarwal S, Kumar S, Topaloglu O. EE325 Hospitalizations From Veno-Occlusive Disease in the US Pacific Region: A Six-Cohort Analysis of National In-Patient Data (2016-2020). Value in Health. 2024;27(12):S118-S119. http://dx.doi.org/10.1016/j.jval.2024.10.607

4. Aggarwal S, Topaloglu H, Kumar S, Bela A, Topaloglu O. Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis. Value in Health. 2024;27(12):S21-S22. http://dx.doi.org/10.1016/j.jval.2024.10.113

5. Aggarwal S, Kumar S, Topaloglu O. EE321 Hospitalization Burden of Congenital Adrenal Hyperplasia in New England: A Six-Cohort Analysis of National In-Patient Data (2016-2020). Value in Health. 2024;27(12):S118. http://dx.doi.org/10.1016/j.jval.2024.10.603

6. Aggarwal S, Kumar S, Topaloglu O. EE322 Understanding Real-World Trends in High Costs, Comorbidities, and Mortality: A Percentile-Based Cohort Comparison in Severe Obesity. Value in Health. 2024;27(12):S118. http://dx.doi.org/10.1016/j.jval.2024.10.604

7. Aggarwal S, Kumar S, Bela A, Topaloglu J. EE323 Hospitalization Burden of Crohn's Disease and Ulcerative Colitis in the Middle Atlantic: A Six-Cohort Analysis of Pooled National In-Patient Data (2016-2020). Value in Health. 2024;27(12):S118. http://dx.doi.org/10.1016/j.jval.2024.10.605

8. Aggarwal S, Kumar S, Topaloglu O. EE324 Hospitalization Burden of Continuous Spikes and Waves During Slow-Wave Sleep (CSWS) in the Middle Atlantic: A Six-Cohort Analysis of Pooled National In-Patient Data (2016-2020). Value in Health. 2024;27(12):S118. http://dx.doi.org/10.1016/j.jval.2024.10.606

9. Aggarwal S, Topaloglu J, Quevedo L, Kumar S, Aranaz G, Topaloglu O. HPR246 Oncology Drug Prices in the United States and Spain: Implications for Pricing Strategy and Drug Access. Value in Health. 2024;27(12):S322. http://dx.doi.org/10.1016/j.jval.2024.10.1670

10. Aggarwal S, Kumar S, Topaloglu O. HTA227 Evaluating the Importance of Patient Input in NICE Highly Specialized Technology (HST) Assessments: Insights From Review Reports. Value in Health. 2024;27(12):S398-S399. http://dx.doi.org/10.1016/j.jval.2024.10.2052

11. Aggarwal S, Kumar S, Topaloglu O. HTA228 Missed Opportunities in Cost-Effectiveness Analyses for Rare Disease Treatments: A Systematic Review of Uncaptured Benefits Reported in NICE Highly Specialized Technology Assessments. Value in Health. 2024;27(12):S399. http://dx.doi.org/10.1016/j.jval.2024.10.2053

12. Aggarwal S, Kumar S, Topaloglu O. HTA230 Indirect Treatment Comparisons in NICE Highly Specialized Technology Assessments. Value in Health. 2024;27(12):S399. http://dx.doi.org/10.1016/j.jval.2024.10.2055

13. Aggarwal S, Kumar S, Topaloglu O. MSR174 Leveraging Chat-GPT for Conducting Systematic Literature Reviews. Value in Health. 2024;27(12):S472. http://dx.doi.org/10.1016/j.jval.2024.10.2408

14. Aggarwal S, Kumar S, Topaloglu O. HTA229 Feasibility Assessment for Using Chat-GPT for Developing Global Value Dossier. Value in Health. 2024;27(12):S399. http://dx.doi.org/10.1016/j.jval.2024.10.2054

15. Aggarwal S, Kumar S, Topaloglu O. HTA226 Lack of Face Validity in Health Technology Assessments: Systematic Review of NICE Assessments and Lessons Learned. Value in Health. 2024;27(12):S398. http://dx.doi.org/10.1016/j.jval.2024.10.2051

16. Aggarwal S, Kumar S, Topaloglu O. MSR173 Using Chat-GPT for Completing Quality Assessment Questionnaires in Systematic Literature Reviews. Value in Health. 2024;27(12):S472. http://dx.doi.org/10.1016/j.jval.2024.10.2407

17. Gebrehiwet P, Aggarwal S, Topaloglu O, Chiò A. Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis. Expert Review of Pharmacoeconomics and Outcomes Research. 2024;24(3):447-458. http://dx.doi.org/10.1080/14737167.2024.2306819

18. Aggarwal S, Kumar S, Topaloglu O. RWD49 Burden of Hospitalizations in Amyotrophic Lateral Sclerosis (ALS): Comparison of Medicare and Private Payer Populations. Value in Health. 2023;26(6):S369. http://dx.doi.org/10.1016/j.jval.2023.03.2078

19. Aggarwal S, Kumar S, Topaloglu O. Insights and Lessons from Systematic Literature Review of Budget Impact Model Methodologies for United States Payers. Value in Health. 2023;26(6):S75. http://dx.doi.org/10.1016/j.jval.2023.03.391

20. Aggarwal S, Kumar S, Topaloglu O. EE193 Burden of Severe Infections in Primary Immunodeficiency (PI) Diseases. Value in Health. 2023;26(6):S94. http://dx.doi.org/10.1016/j.jval.2023.03.494

21. Aggarwal S, Kumar S, Topaloglu O. EE552 Importance of Half Cycle Correction for Cost-Effectiveness Analysis: Case Study of Sacubitril/Valsartan Vs in Enalapril Heart Failure with Reduced Ejection Fraction. Value in Health. 2023;26(6):S160. http://dx.doi.org/10.1016/j.jval.2023.03.2530

22. Aggarwal S, Topaloglu O, Kumar S. RWD24 Veno-Occlusive Disease (VOD) Incidence and Treatment Trends Insights from Latest Systematic Review of Case Reports (2018-2023). Value in Health. 2023;26(6):S364-S365. http://dx.doi.org/10.1016/j.jval.2023.03.2054

23. Aggarwal S, Topaloglu J, Kumar S, Bela A, Topaloglu O. HPR64 Implications of Inflation Reduction Act (IRA) on Budget Impact and Cost-Effectiveness Modeling. Value in Health. 2023;26(6):S222. http://dx.doi.org/10.1016/j.jval.2023.03.1211

24. Aggarwal S, Kumar S, Topaloglu O. RWD172 Incidence and Burden of Bronchiectasis in Patients with Primary Immunodeficiency (PI) Diseases. Value in Health. 2023;26(6):S394. http://dx.doi.org/10.1016/j.jval.2023.03.2200

25. Aggarwal S, Kumar S, Bela A, Topaloglu O. HTA44 Economic Modeling Insights for Ultra Orphan Drugs Based on Review of NICE Highly Specialized Technology (HST) Assessment Reports. Value in Health. 2023;26(6):S266. http://dx.doi.org/10.1016/j.jval.2023.03.1473

26. Aggarwal S, Topaloglu H, Kumar S, Bela A, Topaloglu O. RWD170 Understanding Burden of Veno-Occlusive Disease (VOD): Comparison of Hospital Stays with Vod Principal Versus Secondary Diagnosis. Value in Health. 2023;26(6):S393-S394. http://dx.doi.org/10.1016/j.jval.2023.03.2198

27. Aggarwal S, Kumar S, Bela A, Topaloglu O. EE200 Simple Approach for Developing Parametric Survival Based Cost-Effectiveness Analysis (CEA): Case Study of Heart Failure with Reduced Ejection Fraction (HFREF). Value in Health. 2023;26(6):S95-S96. http://dx.doi.org/10.1016/j.jval.2023.03.501

28. Aggarwal S, Kumar S, Topaloglu J, Bela A, Topaloglu O. HTA9 Evidence Generation Strategy and Insights for Rare Diseases: Case Studies of Mistakes Identified By NICE in Highly Specialized Technology (HST) Assessments. Value in Health. 2023;26(6):S260. http://dx.doi.org/10.1016/j.jval.2023.03.1438

29. Harrington A, Hartog N.L, Wu E.Y, Rider N.L, Aggarwal S. EE308 Estimated Annual Costs Among Patients with Activated PI3K Delta Syndrome. Value in Health. 2023;26(6):S115. http://dx.doi.org/10.1016/j.jval.2023.03.609

30. Aggarwal S, Kumar S, Topaloglu O. RWD113 Understanding Burden and Drivers of Long Hospital Length of Stay in Patients with Heart Failure with Reduced Ejection Fraction (HFREF). Value in Health. 2023;26(6):S382. http://dx.doi.org/10.1016/j.jval.2023.03.2142

31. Aggarwal S, Topaloglu H, Kumar S, Bela A, Topaloglu O. RWD98 Understanding the Role of Real-World Evidence for Reimbursement and Market Access of Ultra Orphan Drugs: Insights and Lessons from Case Studies of NICE Highly Specialized Technology (HST) Assessment Reports. Value in Health. 2023;26(6):S379. http://dx.doi.org/10.1016/j.jval.2023.03.2127

32. Mehanna R, Stimming E.F, Haubenberger D, Klepitskaya O, Aggarwal S, Kumar S, Topaloglu O, Goldstein J, Kayson E, Serbin M. Indirect Treatment Comparison of Valbenazine with Deutetrabenazine for Improvement in Total Maximal Chorea Score in Huntington Disease. Journal of Huntington's Disease. 2023;12:S32-S33. http://dx.doi.org/10.3233/JHD239005

33. Aggarwal S, Topaloglu J, Kumar S, Bela A, Topaloglu O. HTA216 Assessment of Key Drivers of Economic Evaluations for Digital Health and Medical Technologies: Insights and Lessons From Review of NICE Medical Technology Assessment Reports (2010-2022). Value in Health. 2022;25(12):S339. http://dx.doi.org/10.1016/j.jval.2022.09.1674

34. Aggarwal S, Bela A, Topaloglu H, Kumar S, Topaloglu O. HTA83 Role of Quality of Life in Health Technology Assessment Agency Final Recommendations: Insights and Lessons From Review of NICE Technology Assessment Reports (2019-2022). Value in Health. 2022;25(12):S312. http://dx.doi.org/10.1016/j.jval.2022.09.1542

35. Gebrehiwet P, Aggarwal S, Topaloglu O, Chio A. EE605 Feasibility Assessment of Using MiToS Staging System for Conducting Health Economic Analysis in Amyotrophic Lateral Sclerosis (ALS). Value in Health. 2022;25(12):S174. http://dx.doi.org/10.1016/j.jval.2022.09.844

36. Aggarwal S, Topaloglu H, Kumar S, Bela A, Topaloglu O. RWD16 Role of Real-World Evidence for Treatments Granted Access Under Cancer Drugs Fund: Lessons and Insights From Review of NICE Technology Assessment Reports (2019-2022). Value in Health. 2022;25(12):S450-S451. http://dx.doi.org/10.1016/j.jval.2022.09.2241

37. Aggarwal S, Topaloglu J, Kumar S, Bela A, Topaloglu O. HTA36 Value of Real-World Evidence for Treatments for Ultra Orphan or Rare Diseases: Lessons and Insights From Review of NICE Highly Specialized Technology Assessment Reports (2016-2022). Value in Health. 2022;25(12):S303. http://dx.doi.org/10.1016/j.jval.2022.09.1496

38. Aggarwal S, Kumar S, Bela A, Topaloglu O. Systematic Literature Review and Meta-Analysis of Endoscopic Improvement for Treatment of Moderate-Severe Ulcerative Colitis. Value in Health. 2022;25(12):S26. http://dx.doi.org/10.1016/j.jval.2022.09.127

39. Aggarwal S, Topaloglu H, Bela A, Kumar S, Topaloglu O. EE613 Burden of Hospitalization, Costs and Co-Morbidities in Medicare Patients With Chronic Graft Versus Host Disease: Analysis of National In-Patient Hospital Database. Value in Health. 2022;25(12):S176. http://dx.doi.org/10.1016/j.jval.2022.09.852

40. Aggarwal S, Topaloglu O, Kumar S, Bela A. Comparison of Relapse Rates in Ulcerative Colitis Patients With Mayo Endoscopic Score of 0 or 1: Systematic Literature Review and Meta-Analysis. Value in Health. 2022;25(12):S19. http://dx.doi.org/10.1016/j.jval.2022.09.092

41. Aggarwal S, Topaloglu H, Kumar S, Bela A, Topaloglu O. Burden of Hospitalization, Costs and Co-Morbidities in Patients With Chronic Lymphocytic Leukemia: Analysis of Real-World Evidence Using National In-Patient Hospital Database. Value in Health. 2022;25(12):S66. http://dx.doi.org/10.1016/j.jval.2022.09.320

42. Aggarwal S, Topaloglu J, Kumar S, Bela A, Topaloglu O. Understanding Evidence Requirements for Diagnostic Devices for Reimbursement and Market Access: Insights and Lessons From Review of NICE Diagnostics Assessment Reports (2011-2022). Value in Health. 2022;25(12):S11. http://dx.doi.org/10.1016/j.jval.2022.09.059

43. Aggarwal S, Kumar S, Topaloglu H, Bela A, Topaloglu O. CO119 Systematic Review and Meta-Analysis of Mucosal Healing Outcomes With Biologics in Treatment of Ulcerative Colitis and Crohn's Disease. Value in Health. 2022;25(12):S41. http://dx.doi.org/10.1016/j.jval.2022.09.197

44. Aggarwal S, Topaloglu H, Kumar S, Bela A, Topaloglu O. RWD79 Burden of Hospitalization, Costs and Comorbidities in Medicaid Patients With Veno-Occlusive Disease (VOD): Analysis of National In-Patient Hospital Database. Value in Health. 2022;25(12):S464. http://dx.doi.org/10.1016/j.jval.2022.09.2304

45. Aggarwal S, Topaloglu O, Kumar S. Burden of hospitalizations, costs, and co-morbidities in Medicaid patients with sickle cell disease: Analysis of national in-patient hospital database. Journal of Managed Care and Specialty Pharmacy. 2022;28(10):S38. Full text link not provided.

46. Aggarwal S, Topaloglu O, Kumar S, Bela A. Hospitalization, costs, and comorbidities in Medicaid patients with veno-occlusive disease: Analysis of national in-patient hospital database. Journal of Managed Care and Specialty Pharmacy. 2022;28(10):S43. Full text link not provided.

47. Aggarwal S, Topaloglu O, Kumar S. Endoscopic improvement with treatments for moderate-severe ulcerative colitis: Systematic review and meta-analysis of randomized control trials. Journal of Managed Care and Specialty Pharmacy. 2022;28(10):S91. Full text link not provided.

48. Corbacioglu S, Topaloglu O, Aggarwal S. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Clinical Drug Investigation. 2022;42(6):465-476. http://dx.doi.org/10.1007/s40261-022-01140-y

49. Aggarwal S, Kumar S, Bela A, Topaloglu O. BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE. HemaSphere. 2022;6. http://dx.doi.org/10.1097/01.HS9.0000852292.38263.b8

50. Aggarwal S, Kumar S, Topaloglu H, Bela A, Topaloglu O. BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH SICKLE CELL DISEASE (SCD): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE. HemaSphere. 2022;6. http://dx.doi.org/10.1097/01.HS9.0000852292.38263.b8

51. Aggarwal S, Kumar S, Topaloglu H, Bela A, Topaloglu O. BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE. HemaSphere. 2022;6. http://dx.doi.org/10.1097/01.HS9.0000852292.38263.b8

52. Aggarwal S, Kumar S, Bela A, Topaloglu O. BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH VENOOCCLUSIVE DISEASE (VOD): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE. HemaSphere. 2022;6. http://dx.doi.org/10.1097/01.HS9.0000852292.38263.b8

53. Aggarwal S, Kumar S, Bela A, Topaloglu O. BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICARE PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE: ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE. HemaSphere. 2022;6. http://dx.doi.org/10.1097/01.HS9.0000852292.38263.b8

54. Aggarwal S, Kumar S, Bela A, Topaloglu H. PCV27 Hospital Length of Stay, Total Costs and Comorbidities in Patients with Acute Pericarditis: Analysis of National In-patient Hospital Database. Value in Health. 2021;24:S71-S72. http://dx.doi.org/10.1016/j.jval.2021.04.367

55. Aggarwal S, Kumar S, Bela A, Topaloglu H. PUK11 Comparison of Hospitalization Burden of Hyperkalemia in Medicaid Patients By Ethnicity: A Propensity Score Matched Analysis of in-Patient Claims Database. Value in Health. 2021;24:S236. http://dx.doi.org/10.1016/j.jval.2021.04.1179

56. Aggarwal S, Kumar S, Bela A, Topaloglu H. PSU10 Comparison of Burden of Hospitalizations in Acute, Chronic and Acute on Chronic Graft-Versus Host Disease (GVHD): A Propensity Score Matched Analysis of In-Patient Claims Database. Value in Health. 2021;24:S225. http://dx.doi.org/10.1016/j.jval.2021.04.1129

57. Aggarwal S, Kumar S, Bela A, Topaloglu H. PRS4 Burden of Hospitalizations in Patients with Chronic Rhinosinusitis (CRS) with and without Nasal Polyps: A Propensity Score Matched Analysis of In-Patient Claims Database. Value in Health. 2021;24:S213. http://dx.doi.org/10.1016/j.jval.2021.04.1068

58. Aggarwal S, Bela A, Kumar S, Topaloglu H. PMU19 Comparison of Burden of Hospitalizations in Rheumatoid Arthritis (RA), Crohns Disease (CD) and Ulcerative Colitis (CD) Patients Insured By Medicaid: A Propensity Score Matched Analysis of in-Patient Claims Database. Value in Health. 2021;24:S148. http://dx.doi.org/10.1016/j.jval.2021.04.731

59. Aggarwal S, Kumar S, Bela A, Topaloglu H. PGI15 Comparison of Burden of Hospitalizations in Ulcerative Colitis (UC) and Crohn's Disease (CD) Patients with and without Surgery: A Propensity Score Matched Analysis of In-Patient Claims Database. Value in Health. 2021;24:S97. http://dx.doi.org/10.1016/j.jval.2021.04.505

60. Aggarwal S, Bela A, Kumar S, Topaloglu H. PRO25 Trend in Hospital Length of Stay, Costs and Comorbidities in Patients with Veno-Occlusive Disease (VOD): Analysis of National in-Patient Hospital Database. Value in Health. 2021;24:S202. http://dx.doi.org/10.1016/j.jval.2021.04.1010

61. Aggarwal S, Bela A, Kumar S, Topaloglu H. PDB12 Hospital Burden of Chronic Gout with and without Tophus Insured By Medicaid: A Propensity Score Matched Analysis of in-Patient Claims Database. Value in Health. 2021;24:S79. http://dx.doi.org/10.1016/j.jval.2021.04.410

62. Aggarwal S, Kumar S, Bela A, Topaloglu H. PRO22 Hospital Length of Stay, Total Costs and Comorbidities in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis of National In-patient Hospital Database. Value in Health. 2021;24:S201. http://dx.doi.org/10.1016/j.jval.2021.04.1007

63. Aggarwal S, Bela A, Kumar S, Topaloglu H. PND31 Comparison of Burden of Hospitalizations in Epilepsy, Migraine and Sleep Disorders: A Propensity Score Matched Analysis of In-Patient Claims Database. Value in Health. 2021;24:S164. http://dx.doi.org/10.1016/j.jval.2021.04.815

64. Aggarwal S, Wang A, Topaloglu O, Diamond M.P. Quality of Life Outcomes in Treatments for Symptomatic Uterine Fibroids: A Systematic Literature Review. Journal of Minimally Invasive Gynecology. 2020;27(7):S127-S128. http://dx.doi.org/10.1016/j.jmig.2020.08.228

65. Rafique Z, Aggarwal S, Topaloglu O, Cornea G, Conrad A, Peacock F. Trends in emergency department use in patients diagnosed with hyperkalaemia: An analysis of a u.s. national emergency department database. Nephrology Dialysis Transplantation. 2020;35(SUPPL 3). http://dx.doi.org/10.1093/ndt/gfaa142.P0780

66. Ungaro R.C, Aggarwal S, Topaloglu O, Lee W.-J, Clark R, Colombel J.-F. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease. Alimentary Pharmacology and Therapeutics. 2020;51(9):831-842. http://dx.doi.org/10.1111/apt.15685

67. Aggarwal S, Bela A, Topaloglu O. PCN82 BURDEN OF HOSPITALIZATIONS IN MULTIPLE MYELOMA WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANT: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S38. http://dx.doi.org/10.1016/j.jval.2020.04.1584

68. Aggarwal S, Bela A, Topaloglu O. PCN20 OVERALL RESPONSE AND COMPLETE RESPONSE WITH ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) : A SYSTEMATIC REVIEW AND META-ANALYSIS. Value in Health. 2020;23:S25. http://dx.doi.org/10.1016/j.jval.2020.04.1526

69. Aggarwal S, Kumar S, Topaloglu O. PGI12 COMPARISON OF BURDEN OF HOSPITALIZATIONS IN CROHN'S DISEASE AND ULCERATIVE COLITIS: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S144. http://dx.doi.org/10.1016/j.jval.2020.04.369

70. Aggarwal S, Bela A, Topaloglu O. PIN22 MORTALITY, MORBIDITY AND BURDEN OF HOSPITALIZATIONS IN INFLUENZA PATIENTS WITH LOW AND HIGH COMORBIDITY INDEX: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S172. http://dx.doi.org/10.1016/j.jval.2020.04.497

71. Aggarwal S, Kumar S, Topaloglu O. PSU10 IMPACT OF BILE DUCT INJURY DURING CHOLECYSTECTOMY ON HOSPITAL LENGTH OF STAY AND COSTS: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S366. http://dx.doi.org/10.1016/j.jval.2020.04.1410

72. Aggarwal S, Topaloglu O, Bela A, Topaloglu H. PGI11 COMPARISON OF BURDEN OF HOSPITALIZATIONS IN INFLAMMATORY BOWEL DISEASE (IBD) WITH AND WITHOUT COLORECTAL CANCER: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S144. http://dx.doi.org/10.1016/j.jval.2020.04.368

73. Aggarwal S, Kumar S, Topaloglu O. PMH14 BURDEN OF HOSPITALIZATIONS IN NARCOLEPSY PATIENTS WITH LOW AND HIGH COMORBIDITY INDEX: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S202. http://dx.doi.org/10.1016/j.jval.2020.04.635

74. Aggarwal S, Mayrand K, Topaloglu O. PRO96 BURDEN OF HOSPITALIZATIONS AND SERIOUS INFECTIONS IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS: AN ANALYSIS OF US NATIONAL IN-PATIENT SAMPLE DATABASE. Value in Health. 2020;23:S346. http://dx.doi.org/10.1016/j.jval.2020.04.1317

75. Aggarwal S, Topaloglu O, Kumar S. PCN141 COMPARISON OF BURDEN OF HOSPITALIZATIONS IN ACUTE MYELOID LEUKEMIA WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANT: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S47-S48. http://dx.doi.org/10.1016/j.jval.2020.04.1628

76. Aggarwal S, Bela A, Topaloglu O. PDB30 HOSPITALIZATIONS AND COMORBIDITIES IN CHRONIC GOUT WITH AND WITHOUT TOPHUS: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S113. http://dx.doi.org/10.1016/j.jval.2020.04.218

77. Aggarwal S, Bela A, Topaloglu O. PRO27 HOSPITAL LENGTH OF STAY, COSTS AND COMORBIDITIES IN BETA-THALASSEMIA: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S333. http://dx.doi.org/10.1016/j.jval.2020.04.1255

78. Aggarwal S, Kumar S, Topaloglu O. PRO30 MORTALITY, MORBIDITY, SERIOUS INFECTIONS AND BURDEN OF HOSPITALIZATIONS IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS WITH LOW AND HIGH COMORBIDITY INDEX: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S334. http://dx.doi.org/10.1016/j.jval.2020.04.1258

79. Aggarwal S, Bela A, Topaloglu O. ND2 BURDEN OF HOSPITALIZATIONS IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANT: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S9. http://dx.doi.org/10.1016/j.jval.2020.04.050

80. Aggarwal S, Kumar S, Topaloglu O. PCN56 BURDEN OF HOSPITALIZATIONS IN NON-HODGKIN’S LYMPHOMA WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANT: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S33. http://dx.doi.org/10.1016/j.jval.2020.04.1560

81. Aggarwal S, Bela A, Topaloglu O. PUK12 BURDEN OF HOSPITALIZATIONS IN UTERINE FIBROIDS (UF) PATIENTS WITH LOW AND HIGH COMORBIDITY INDEX: A PROPENSITY SCORE MATCHED ANALYSIS OF IN-PATIENT CLAIMS DATABASE. Value in Health. 2020;23:S379. http://dx.doi.org/10.1016/j.jval.2020.04.1470

82. Tappe W, Aggarwal S, Topaloglu O, Iacobelli M. A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment. Biology of Blood and Marrow Transplantation. 2020;26(3):S131. http://dx.doi.org/10.1016/j.bbmt.2019.12.651

83. Corbacioglu S, Aggarwal S, Topaloglu O, Tappe W. A Systematic Review of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biology of Blood and Marrow Transplantation. 2020;26(3):S133. http://dx.doi.org/10.1016/j.bbmt.2019.12.655

84. Tappe W, Aggarwal S, Topaloglu O, Iacobelli M. A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting. Clinical and Applied Thrombosis/Hemostasis. 2020;26. http://dx.doi.org/10.1177/1076029620935202

85. Richardson P, Aggarwal S, Topaloglu O, Villa K.F, Corbacioglu S. Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) (Bone Marrow Transplantation, (2019), 54, 12, (1951-1962), 10.1038/s41409-019-0474-8). Bone Marrow Transplantation. 2019;54(12):2117-2119. http://dx.doi.org/10.1038/s41409-019-0507-3

86. Tappe W, Aggarwal S, Topaloglu O, Iacobelli M. A Meta-Analysis Evaluating the Risk of Bleeding-Related Adverse Events with Defibrotide Treatment. Blood. 2019;134. http://dx.doi.org/10.1182/blood-2019-123686

87. Ungaro R, Aggarwal S, Topaloglu O, Lee W.-J, Clark R, Colombel J.-F. Efficacy of early anti-tumor necrosis factor treatment in adult and pediatric patients with Crohn's disease : A systematic review and meta-analysis. United European Gastroenterology Journal. 2019;7(8):355. http://dx.doi.org/10.1177/205064061985467

88. Aggarwal S, Serbin M, Yonan C. PND12 CLINICAL EFFICACY OF VALBENAZINE AND DEUTETRABENAZINE FOR THE TREATMENT OF TARDIVE DYSKINESIA: INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS. Value in Health. 2019;22:S272. http://dx.doi.org/10.1016/j.jval.2019.04.1285

89. Richardson P, Aggarwal S, Topaloglu O, Villa K.F, Corbacioglu S. Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplantation. 2019;. http://dx.doi.org/10.1038/s41409-019-0474-8

90. Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. Journal of Comparative Effectiveness Research. 2019;8(13):1077-1088. http://dx.doi.org/10.2217/cer-2019-0059

91. Richardson P.G, Carreras E, Pagliuca A, Soiffer R.J, Antin J.H, Ho V.T, Aggarwal S, Topaloglu O, Villa K.F, Mohty M. Pooled analysis of defibrotide studies in treatment of adult patients with veno-occlusive disease/ sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT. Bone Marrow Transplantation. 2019;53:63-64. http://dx.doi.org/10.1038/s41409-018-0318-y

92. Corbacioglu S, Aggarwal S, Topaloglu O, Martin R, Villa K. Pooled analysis of defibrotide studies in pediatric patients treated for veno-occlusive disease/sinusoidal obstruction syndrome. Pediatric Blood and Cancer. 2018;65:S223. http://dx.doi.org/10.1002/pbc.27455

93. Aggarwal S, Serbin M, Yonan C. Meta-analysis of randomized controlled trials of valbenazine and deutetrabenazine efficacy for treatment of tardive dyskinesia. Journal of Managed Care and Specialty Pharmacy. 2018;24(10 A):S49-S50. http://dx.doi.org/10.18553/jmcp.2018.24.10-a.s1

94. Aggarwal S, Topaloglu O, Kumar S. Using real-world evidence for health technology assessment submissions: Lessons and insights from review of NICE's technology assessment reports (2016-2017). Value in Health. 2018;21:S7. Full text link not provided.

95. Aggarwal S, Topaloglu O, Kumar S. Trends in HTA submissions for rare diseases: Insights from review of nice's highly specialized technology (HST) assessment reports. Value in Health. 2018;21:S264-S265. Full text link not provided.

96. Aggarwal S, Topaloglu O, Kumar S. Role of patient assistance program (PAP) in market access and outcomes: Insights from systematic literature review (2013-2017). Value in Health. 2018;21:S99-S100. Full text link not provided.

97. Aggarwal S, Topaloglu O, Kumar S. Cost effectiveness of anti-PD-1/PD-L1 treatments: Systematic review of published studies. Value in Health. 2018;21:S29. Full text link not provided.

98. Aggarwal S, Topaloglu O, Kumar S. Real world evidence for effectiveness of biologics for rheumatoid arthritis: Systematic literature review of population based registry studies. Value in Health. 2018;21:S192. Full text link not provided.

99. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in patients with hereditary angioedema: Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S255. Full text link not provided.

100. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in patients with primary immunodeficiency: Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S255. Full text link not provided.

101. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in endometriosis: Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S143. Full text link not provided.

102. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in patients with Crohn's disease: Analysis of us national in-patient data for 2015. Value in Health. 2018;21:S83. Full text link not provided.

103. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay, seasonality and costs in patients with respiratory syncytial virus infection: Analysis of US national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses. Value in Health. 2018;21:S154. Full text link not provided.

104. Aggarwal S, Kumar S, Topaloglu O. Hospital lenght of stay and costs in patients with post operative wound infection: Analysis of US national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses. Value in Health. 2018;21:S154. Full text link not provided.

105. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay, seasonality and costs in patients with influenza infection: Analysis of us national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses. Value in Health. 2018;21:S154-S155. Full text link not provided.

106. Aggarwal S, Kumar S, Topaloglu O. Hospital lenght of stay and costs in patients with urinary track infections: Analysis of US national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses. Value in Health. 2018;21:S267. Full text link not provided.

107. Aggarwal S, Kumar S, Topaloglu O. Hospital lenght of stay and costs in patients with acute myeloid leukemia: Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S23. Full text link not provided.

108. Aggarwal S, Kumar S, Topaloglu O. Burden of hospitalization in lung cancer patients with brain metastases: Analysis of us national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses. Value in Health. 2018;21:S23. Full text link not provided.

109. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in patients with hepatocellular carcinoma (HCC): Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S34. Full text link not provided.

110. Aggarwal S, Kumar S, Topaloglu O. Hospitalization lenght of stay and costs in patients with multiple myeloma: Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S34. Full text link not provided.

111. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in patients with chronic lymphoid leukemia: Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S24. Full text link not provided.

112. Aggarwal S, Kumar S, Topaloglu O. Trends in hospitalization lenght of stay and costs in patients with peripheral T-cell lymphoma (PTCL): Analysis of US national in-patient data for 2015. Value in Health. 2018;21:S34. Full text link not provided.

113. Richardson P.G, Aggarwal S, Topaloglu O, Villa K, Corbacioglu S. Pooled analysis of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation or chemotherapy without hematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice. 2018;24(2):18-19. http://dx.doi.org/10.1177/1078155217751308

114. Caroff S.N, Aggarwal S, Yonan C. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: A systematic review. Journal of Comparative Effectiveness Research. 2018;7(2):135-148. http://dx.doi.org/10.2217/cer-2017-0065

115. Colombel J.-F, Ungaro R, Aggarwal S, Topaloglu O, Skup M, Lee W.-J. Efficacy and safety of early biologic treatment of Crohn's disease in adult and paediatric patients: A systematic review. Journal of Crohn's and Colitis. 2018;12:S461. Full text link not provided.

116. Richardson P.G, Aggarwal S, Topaloglu O, Villa K, Corbacioglu S. Pooled analysis of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT. Blood. 2017;130. Full text link not provided.

117. Caroff S.M, Aggarwal S, Yonan C. Feasibility of a comparative meta-analysis of VMAT2 inhibitors for the treatment of tardive dyskinesia. Value in Health. 2017;20(5):A189. Full text link not provided.

118. Caroff S, Aggarwal S, Yonan C. Systematic review of valbenazine and tetrabenazine for treatment of tardive dyskinesia. Journal of Managed Care and Specialty Pharmacy. 2017;23:S60. Full text link not provided.

119. Erman M, Aggarwal S, Topaloglu O, Bujanover S, Black J, Villa K.F. Efficacy of sodium oxybate for treatment of excessive daytime sleepiness in narcolepsy: Meta-analysis of randomized controlled trials. Sleep. 2017;40:A249. Full text link not provided.

120. Aggarwal S, Kumar S, Topaloglu O. Insights from analysis of formulary coverage trends for generics with high price increases. Journal of Managed Care and Specialty Pharmacy. 2016;22:S93. Full text link not provided.

121. Aggarwal S, Kumar S, Topaloglu H. Bayesian network meta-analysis to assess comparative effectiveness of beta-blockers in patients with heart failure and reduced ejection fraction. Value in Health. 2016;19(3):A2. Full text link not provided.

122. Aggarwal S, Topaloglu H. Trends in ER visits due to hyperkalemia in the United States. Value in Health. 2016;19(3):A42. Full text link not provided.

123. Aggarwal S, Kumar S, Topaloglu H. Systematic review of burden of hyperkalemia due to angiotensin enzyme converting inhibitors. Value in Health. 2016;19(3):A42. Full text link not provided.

124. Wallick C, Aggarwal S, Yonan C, Shulman K.J. Rapid relief of pain in episodic migraine was associated with lower self-reported disability and lower rates of migraine-associated symptoms: A secondary analysis of the compass trial. Value in Health. 2016;19(3):A60. Full text link not provided.

125. Aggarwal S, Kumar S, Topaloglu H. Trends in design, conduct, and outcomes measures for patient registries for multiple sclerosis. Value in Health. 2016;19(3):A70. Full text link not provided.

126. Aggarwal S, Kumar S, Topaloglu H. Latest trends in design of clinical trials for stroke treatment with stem cells. Value in Health. 2016;19(3). Full text link not provided.

127. Disease Aggarwal S, Kumar S, Topaloglu H. Latest trends in design of pivotal clinical trials for huntington's. Value in Health. 2016;19(3):A77. Full text link not provided.

128. Aggarwal S, Kumar S, Topaloglu H. Trends in design of pivotal phase III clinical trials for alpha 1 anti trypsin deficiency disorder. Value in Health. 2016;19(3). Full text link not provided.

129. Aggarwal S, Kumar S, Topaloglu H. Latest trends in design of pivotal phase III clinical trials for hemophilia A And B. Value in Health. 2016;19(3):A103. Full text link not provided.

130. Aggarwal S, Kumar S, Topaloglu H. Latest trends in design of pivotal phase III clinical trials for partial onset of seizures. Value in Health. 2016;19(3):A103. Full text link not provided.

131. Aggarwal S, Kumar S, Topaloglu H. Latest trends in design of pivotal phase III clinical trials for peripheral T-Cell lymphoma. Value in Health. 2016;19(3):A104. Full text link not provided.

132. Aggarwal S, Kumar S, Topaloglu H. Trends in design of pivotal phase III clinical trials for cluster headache disorder. Value in Health. 2016;19(3):A104. Full text link not provided.

133. Aggarwal S, Kumar S, Topaloglu H. Latest trends in design of clinical trials for real-world health economic evidence generation. Value in Health. 2016;19(3):A105. Full text link not provided.

134. Aggarwal S, Topaloglu H. Systematic review of design of latest real-world observational studies in multiple myeloma. Value in Health. 2016;19(3). Full text link not provided.

135. Aggarwal S, Kumar S, Topaloglu H. Analysis of access to harvoni for medicare patients in all fifty states in the US. Value in Health. 2016;19(3):A168. Full text link not provided.

136. Aggarwal S, Kumar S, Topaloglu H. Patient access to oral breakthrough cancer drugs in The United States. Value in Health. 2016;19(3):A168. Full text link not provided.

137. Aggarwal S, Topaloglu H. Systematic review of cost-effectiveness analyses of ultra-orphan therapies. Value in Health. 2016;19(3):A247. Full text link not provided.

138. Aggarwal S, Kumar S, Topaloglu H. Price increases for generics imposing new market access challenge: Insights from analysis of formulary coverage trends for generics. Value in Health. 2016;19(3):A260. Full text link not provided.

139. Aggarwal S, Kumar S, Topaloglu H. Market access insights from review of us formulary coverage trends for top 100 selling drugs. Value in Health. 2016;19(3):A280. Full text link not provided.

140. Aggarwal S, Kumar S, Topaloglu H. Analysis of essential health benefit benchmark plans in the United States. Value in Health. 2016;19(3):A280. Full text link not provided.

141. Aggarwal S, Kumar S, Topaloglu H. Bayesian network meta-analysis on prevention of stroke for patent foramen ovale closure. Value in Health. 2016;19(3):A298. Full text link not provided.

142. Aggarwal S, Kumar S, Topaloglu H. Harvoni access and utilization trends in fifty medicaid programs in the United States. Value in Health. 2016;19(3):A318. Full text link not provided.

143. Velez F, Aggarwal S. Cost-effectiveness of eslicarbazepine acetate monotherapy in partial-onset epilepsy. Journal of Managed Care and Specialty Pharmacy. 2016;22:S75-S76. Full text link not provided.

144. Wallick C, Aggarwal S, Yonan C, Shulman K. Rapid relief of pain in episodic migraine is associated with lower self-reported disability and lower rates of migraine associated symptoms: A secondary analysis of the COMPASS trial. Journal of Managed Care and Specialty Pharmacy. 2016;22:S76. Full text link not provided.

145. Aggarwal S, Kumar S, Topaloglu H. Network meta-analysis on prevention of stroke for patent foramen ovale closure. Value in Health. 2015;18(7). Full text link not provided.

146. Aggarwal S, Topaloglu H, Kumar S. Network meta-analysis to assess comparative effectiveness of beta-blockers in patients with heart failure and reduced ejection fraction. Value in Health. 2015;18(7):A375. Full text link not provided.

147. Aggarwal S, Topaloglu H, Kumar S. Trends in emergency room visits due to hyperkalemia in the United States. Value in Health. 2015;18(7):A386. Full text link not provided.

148. Aggarwal S, Topaloglu H, Kumar S. Systematic review of hyperkalemia due to angiotensin enzyme converting inhibitors. Value in Health. 2015;18(7):A396. Full text link not provided.

149. Aggarwal S, Kumar S, Topaloglu H. Review of patient reported outcomes in glaucoma. Value in Health. 2015;18(7):A426. Full text link not provided.

150. Aggarwal S, Topaloglu H, Kumar S. Systematic review of burden of cutaneous t-cell lymphoma. Value in Health. 2015;18(7):A438. Full text link not provided.

151. Aggarwal S, Topaloglu H, Kumar S. Systematic review of burden of pancreatic cancer. Value in Health. 2015;18(7):A439. Full text link not provided.

152. Aggarwal S, Topaloglu H, Kumar S. Systematic review on use of economic evidence in clinical guidelines. Value in Health. 2015;18(7):A516. Full text link not provided.

153. Aggarwal S, Topaloglu H, Kumar S. Policy implications of affordable care act on us market access. Value in Health. 2015;18(7):A518. Full text link not provided.

154. Aggarwal S, Topaloglu H, Kumar S. Systematic review of cost effectiveness of ultra-orphan therapies. Value in Health. 2015;18(7):A533. Full text link not provided.

155. Aggarwal S, Kumar S, Topaloglu H. Systematic review of FDA breakthrough therapy designated products. Value in Health. 2015;18(7):A541. Full text link not provided.

156. Aggarwal S, Kumar S, Topaloglu H. Overview of nub process for in-patient drugs and devices in German. Value in Health. 2015;18(7):A546. Full text link not provided.

157. Aggarwal S, Topaloglu H, Kumar S. Impact of essential health benefit benchmark plans on us market access. Value in Health. 2015;18(7):A546. Full text link not provided.

158. Aggarwal S, Topaloglu H, Kumar S. Ultra orphan and cancer drug pricing trends in the us and the UK. Value in Health. 2015;18(7):A547. Full text link not provided.

159. Aggarwal S, Topaloglu H, Kumar S. Probiotics significantly reduce mortality in preterm newborns with necrotising enterocolitis: Results of large network meta-analysis. Value in Health. 2015;18(7):A576. Full text link not provided.

160. Aggarwal S, Kumar S, Topaloglu H. Comparison of network meta-analysis and traditional meta-analysis for prevention of relapses in multiple sclerosis. Value in Health. 2015;18(7):A660. Full text link not provided.

161. Aggarwal S, Topaloglu J, Kumar S. Comprehensive review of managed care formulary access trends for top 100 selling drugs. Journal of Managed Care and Specialty Pharmacy. 2015;21:S11-S12. Full text link not provided.

162. Wallick C, Shulman K, Siegert S, Aggarwal S, Yonan C. The treatment evidence disconnect between what migraine patients want and what is reported in trial literature: A systematic literature review of rapid relief outcomes in migraine therapy trials. Journal of Managed Care and Specialty Pharmacy. 2015;21:S49. Full text link not provided.

163. Aggarwal S, Topaloglu H, Kumar S. Systematic review of cost effectiveness of ultra-orphan therapies: Lesson learned from published HTAs and studies. Value in Health. 2015;18(3). Full text link not provided.

164. Aggarwal S, Topaloglu H. Impact of 2014 essential health benefit benchmark plans on us managed care. Value in Health. 2015;18(3):A73. Full text link not provided.

165. Aggarwal S, Topaloglu H, Kumar S. Comparative effectiveness, approval rates and pricing of drugs with FDA 's breakthrough therapy designations. Value in Health. 2015;18(3):A87. Full text link not provided.

166. Topaloglu H, Aggarwal S. Impact of new changes due to affordable care act on us market access. Value in Health. 2015;18(3):A88. Full text link not provided.

167. Aggarwal S, Kumar S, Topaloglu H. Overview and importance of nub process for market access of inpatient drugs and devices in Germany. Value in Health. 2015;18(3):A89. Full text link not provided.

168. Aggarwal S, Kumar S, Topaloglu H. Trends in use of health economic evidence for developing clinical guidelines. Value in Health. 2015;18(3):A99. Full text link not provided.

169. Aggarwal S, Topaloglu H, Kumar S. Patient reported outcomes in Glaucoma a Systematic review. Value in Health. 2015;18(3):A184. Full text link not provided.

170. Aggarwal S, Topaloglu H, Kumar S. Systematic review of epidemiology and burden of pancreatic cancer. Value in Health. 2015;18(3). Full text link not provided.

171. Aggarwal S, Topaloglu H. Systematic review of epidemiology and burden of cutaneous T-cell lymphoma. Value in Health. 2015;18(3):A199. Full text link not provided.

172. Kumar S, Aggarwal S, Topaloglu H. Comparison of ultra orphan and cancer drug pricing in the us and the UK. Value in Health. 2015;18(3):A305. Full text link not provided.

173. Diamantidis C.J, Ginsberg J.S, Yoffe M, Lucas L, Prakash D, Aggarwal S, Fink W, Becker S, Fink J.C. Remote usability testing and satisfaction with a mobile health medication inquiry system in CKD. Clinical Journal of the American Society of Nephrology. 2015;10(8):1364-1370. http://dx.doi.org/10.2215/CJN.12591214

174. Lin H.M, Suri A, Webb I.J, Aggarwal S. Relationships between food effects, patient adherence to treatment, and pharmacokinetics of oral anticancer drugs. Journal of Clinical Oncology. 2014;32(15). Full text link not provided.

175. Aggarwal S, Topaloglu H, Kumar S. Adjusting budget impact model based on new changes due to affordable care Act. Value in Health. 2014;17(3):A1. http://dx.doi.org/10.1016/j.jval.2014.03.007

176. Aggarwal S, Topaloglu H. Is FDA's breakthrough therapy designation a game-changing trend for patients and payers?. Value in Health. 2014;17(3):A10. http://dx.doi.org/10.1016/j.jval.2014.03.067

177. Aggarwal S, Topaloglu H. Systematic review of cost effectiveness of top selling products. Value in Health. 2014;17(3):A21. http://dx.doi.org/10.1016/j.jval.2014.03.131

178. Aggarwal S, Topaloglu H. Need for subgroup cost effectiveness analyses for health technology assessments. Value in Health. 2014;17(3):A27. http://dx.doi.org/10.1016/j.jval.2014.03.167

179. Aggarwal S, McGrane M. Trends in use of economic evidence by clinical guidelines. Value in Health. 2014;17(3):A30. http://dx.doi.org/10.1016/j.jval.2014.03.182

180. Aggarwal S, Topaloglu H, Segal J. Meta-analysis of efficacy of etanercept for psoriatic arthritis. Value in Health. 2014;17(3):A42. http://dx.doi.org/10.1016/j.jval.2014.03.251

181. Roy S, Ghosh S.K, Aggarwal S, Yoo A.C. Meta-analysis of anastomotic leak rates following hand-sewn suture versus stapled anastomoses during right colon surgery. Value in Health. 2014;17(3). http://dx.doi.org/10.1016/j.jval.2014.03.396

182. Aggarwal S, Segal J. Patient reported outcomes in castration-resistant prostate cancer. Value in Health. 2014;17(3):A94. http://dx.doi.org/10.1016/j.jval.2014.03.547

183. Aggarwal S, Topaloglu H. Oncology pricing trends in the United States and the United Kingdom (2011-2013). Value in Health. 2014;17(3):A99. http://dx.doi.org/10.1016/j.jval.2014.03.577

184. Aggarwal S, Kumar S, Segal J. Meta-analysis of safety of dabigatran and warfarin for atrial fibrillation. Value in Health. 2014;17(3). http://dx.doi.org/10.1016/j.jval.2014.03.616

185. Aggarwal S, Topaloglu H. Meta-analysis of efficacy of romiplostim for immune idiopathic thrombocytopenia. Value in Health. 2014;17(3). http://dx.doi.org/10.1016/j.jval.2014.03.1313

186. Aggarwal S, Topaloglu H, Kumar S. Cost of in-patient hospitalizations for chronic kidney disease in the United States. Value in Health. 2014;17(3):A293. http://dx.doi.org/10.1016/j.jval.2014.03.1704

187. Aggarwal S.R. What's fueling the biotech engine-2012 to 2013. Nature Biotechnology. 2014;32(1):32-39. http://dx.doi.org/10.1038/nbt.2794

188. Aggarwal S.R. A survey of breakthrough therapy designations. Nature Biotechnology. 2014;32(4):323-330. http://dx.doi.org/10.1038/nbt.2864

189. Aggarwal S, Topaloglu H. Meta-analysis of efficacy of romiplostim for treatment of immune idiopa thic thrombocytopenia. Value in Health. 2013;16(7):A378. http://dx.doi.org/10.1016/j.jval.2013.08.319

190. Aggarwal S, Segal J, Topaloglu H. Systematic review of patient reported outcomes in chronic myeloid leukemia. Value in Health. 2013;16(7). http://dx.doi.org/10.1016/j.jval.2013.08.560

191. Aggarwal S, Segal J, Kumar S. Patient reported outcomes in metastatic castration-resistant prostate cancer. Value in Health. 2013;16(7):A421. http://dx.doi.org/10.1016/j.jval.2013.08.561

192. Aggarwal S, Kumar S, Topaloglu H. Novel market access models for cancer drugs. Value in Health. 2013;16(7):A428. http://dx.doi.org/10.1016/j.jval.2013.08.603

193. Aggarwal S, Topaloglu H, Kumar S. Import ance of subgroup analyses for health technology assessments. Value in Health. 2013;16(7):A462. http://dx.doi.org/10.1016/j.jval.2013.08.802

194. Aggarwal S, McGrane M, Topaloglu H. Systematic review on use of economic evidence by clinical guidelines. Value in Health. 2013;16(7). http://dx.doi.org/10.1016/j.jval.2013.08.945

195. Aggarwal S, Segal J, Topaloglu H. A systematic review of patient reported outcomes in glaucoma. Value in Health. 2013;16(7):A509. http://dx.doi.org/10.1016/j.jval.2013.08.1182

196. Aggarwal S, Segal J. Meta-analysis of safety of dabigatran and warfarin for treatment of atrial fibrillation. Value in Health. 2013;16(7):A515. http://dx.doi.org/10.1016/j.jval.2013.08.1216

197. Aggarwal S, Topaloglu H. Meta-analysis of efficacy of etanercept for treatment of psoriatic arthritis. Value in Health. 2013;16(7):A555. http://dx.doi.org/10.1016/j.jval.2013.08.1450

198. Aggarwal S, Topaloglu H. In-patient hospitalizations for chronic kidney disease in the United States. Value in Health. 2013;16(7). http://dx.doi.org/10.1016/j.jval.2013.08.1876

199. Aggarwal S, Messenger M. Trends in cost effectiveness of high budget impact products. Value in Health. 2013;16(3). http://dx.doi.org/10.1016/j.jval.2013.03.117

200. Aggarwal S, Topaloglu H. Reimbursement and market access of multiple sclerosis products in the united states. Value in Health. 2013;16(3):A109. http://dx.doi.org/10.1016/j.jval.2013.03.519

201. Aggarwal S, Topaloglu H, Messenger M. Meta-analysis for efficacy of romiplostim for treatment of immune idiopathic thrombocytopenia. Value in Health. 2013;16(3). http://dx.doi.org/10.1016/j.jval.2013.03.538

202. Aggarwal S, Segal J. Systematic review of anti-VEGF therapies for metastatic colorectal cancer. Value in Health. 2013;16(3):A128. http://dx.doi.org/10.1016/j.jval.2013.03.622

203. Aggarwal S, Topaloglu H. Budget impact model for cutaneous t-cell lymphoma. Value in Health. 2013;16(3). http://dx.doi.org/10.1016/j.jval.2013.03.644

204. Aggarwal S, Segal J, Messenger M. Patient reported outcomes in chronic myeloid leukemia: A systematic review. Value in Health. 2013;16(3):A147. http://dx.doi.org/10.1016/j.jval.2013.03.721

205. Aggarwal S, Topaloglu H. Novel electronic patient reported outcomes tool for prostate cancer patients. Value in Health. 2013;16(3):A147. http://dx.doi.org/10.1016/j.jval.2013.03.723

206. Aggarwal S, Segal J, Messenger M. Patient reported outcomes in metastatic castration-resistant prostate cancer: A systematic review. Value in Health. 2013;16(3):A149. http://dx.doi.org/10.1016/j.jval.2013.03.734

207. Aggarwal S, Topaloglu H, Kumar S. Cancer drug pricing trends in the united states and the united kingdom (2011-2013). Value in Health. 2013;16(3):A150. http://dx.doi.org/10.1016/j.jval.2013.03.741

208. Aggarwal S, Topaloglu H, Messenger M. Novel reimbursement models for cancer drug market access (2010- 2013). Value in Health. 2013;16(3):A153. http://dx.doi.org/10.1016/j.jval.2013.03.757

209. Aggarwal S, Segal J, Messenger M. Patient reported outcomes in glaucoma a systematic review. Value in Health. 2013;16(3):A178. http://dx.doi.org/10.1016/j.jval.2013.03.895

210. Aggarwal S, Topaloglu H. In-patient hospitalization trends for chronic kidney disease in the United States. Value in Health. 2013;16(3):A181. http://dx.doi.org/10.1016/j.jval.2013.03.911

211. Aggarwal S, Topaloglu H, Messenger M. Meta-analysis for efficacy of etanercept for treatment of psoriatic arthritis. Value in Health. 2013;16(3):A219. http://dx.doi.org/10.1016/j.jval.2013.03.1111

212. Aggarwal S, Topaloglu H, Kumar S, Segal J, McGrane M. Trends in use of health economic evidence for developing clinical guidelines. Value in Health. 2013;16(3):A245. http://dx.doi.org/10.1016/j.jval.2013.03.1248

213. Aggarwal S, Messenger M. Pricing and reimbursement of targeted cancer therapies in russia (2011-2012). Value in Health. 2013;16(3):A260. http://dx.doi.org/10.1016/j.jval.2013.03.1333

214. Aggarwal S, Topaloglu H. Role of subgroup analyses for health technology assessments. Value in Health. 2013;16(3). http://dx.doi.org/10.1016/j.jval.2013.03.1358

215. Aggarwal S, Topaloglu H, Messenger M. Meta-analysis for safety of dabigatran and warfarin for treatment of atrial fibrillation. Value in Health. 2013;16(3):A274. http://dx.doi.org/10.1016/j.jval.2013.03.1421

216. Diamantidis C.J, Zuckerman M, Fink W, Aggarwal S, Prakash D, Fink J.C. Usability testing and acceptance of an electronic medication inquiry system for CKD patients. American Journal of Kidney Diseases. 2013;61(4):644-646. http://dx.doi.org/10.1053/j.ajkd.2012.09.016

217. Aggarwal S. What's fueling the biotech engine-2011 to 2012. Nature Biotechnology. 2012;30(12):1191-1197. http://dx.doi.org/10.1038/nbt.2437

218. Aggarwal S. Comparison of cancer drug prices in the United States and the UK. Value in Health. 2012;15(7):A278. http://dx.doi.org/10.1016/j.jval.2012.08.478

219. Aggarwal S. 2010-2012 global health care reforms and their impact on pricing, access and health outcomes strategy. Value in Health. 2012;15(7):A291. http://dx.doi.org/10.1016/j.jval.2012.08.556

220. Aggarwal S. Role of subgroup analyses for technology assessment and coverage decisions. Value in Health. 2012;15(7):A291. http://dx.doi.org/10.1016/j.jval.2012.08.559

221. Aggarwal S. France market access: Review of 2011-2012 assessments by transparency committee. Value in Health. 2012;15(7). http://dx.doi.org/10.1016/j.jval.2012.08.576

222. Aggarwal S. Emerging drug reimbursement models: Lessons and implications from cancer drug access schemes. Value in Health. 2012;15(7). http://dx.doi.org/10.1016/j.jval.2012.08.599

223. Aggarwal S. Review of cost effectiveness studies of high budget impact drugs (2007-2012). Value in Health. 2012;15(7):A309. http://dx.doi.org/10.1016/j.jval.2012.08.656

224. Aggarwal S. New pricing dynamics in big five EU: Case study of biosimilar GM-CSF products. Value in Health. 2012;15(7):A310. http://dx.doi.org/10.1016/j.jval.2012.08.662

225. Aggarwal S. Systematic review of non-interferon based regimens for chronic hepatitis c treatment. Value in Health. 2012;15(7):A385. http://dx.doi.org/10.1016/j.jval.2012.08.1073

226. Aggarwal S. Emerging market access trends: Pricing and coverage of targeted cancer therapies in Russia (2011-2012). Value in Health. 2012;15(7):A433. http://dx.doi.org/10.1016/j.jval.2012.08.2169

227. Aggarwal S. Access, uptake and utilization management of multiple sclerosis products in the United States. Value in Health. 2012;15(7):A559. http://dx.doi.org/10.1016/j.jval.2012.08.1996

228. Aggarwal S. Cost effectiveness trends of high budget impact drugs (2006-2012). Value in Health. 2012;15(4):A5. http://dx.doi.org/10.1016/j.jval.2012.03.032

229. Aggarwal S. Impact of 2009-2011 global health care reforms on pricing, access and health outcomes strategy. Value in Health. 2012;15(4):A12. http://dx.doi.org/10.1016/j.jval.2012.03.074

230. Aggarwal S. Trends in rate and cost of hospitalizations due to chronic kidney disease (CKD) in the united states. Value in Health. 2012;15(4):A154. http://dx.doi.org/10.1016/j.jval.2012.03.833

231. Aggarwal S. Electronic patient reported outcomes and data tool for chronic disease management (PROCDIM): Case in point prostate cancer. Value in Health. 2012;15(4):A201. http://dx.doi.org/10.1016/j.jval.2012.03.1084

232. Aggarwal S. Systematic review of clinical efficacy and safety outcomes of anti-vegf therapies for metastatic colorectal cancer. Value in Health. 2012;15(4):A210. http://dx.doi.org/10.1016/j.jval.2012.03.1132

233. Aggarwal S. Developing budget impact model for rare diseases: Case in point cutaneous T-cell lymphoma. Value in Health. 2012;15(4):A212. http://dx.doi.org/10.1016/j.jval.2012.03.1147

234. Aggarwal S. Oncology drug prices in the United States and the United Kingdom: Implications for pricing strategy and drug access. Value in Health. 2012;15(4):A232. http://dx.doi.org/10.1016/j.jval.2012.03.1253

235. Aggarwal S. Systematic review of interferon free based regimens for chronic Hepatitis C treatment. Value in Health. 2012;15(4):A237. http://dx.doi.org/10.1016/j.jval.2012.03.1281

236. Aggarwal S. What's fueling the biotech engine-2010 to 2011. Nature Biotechnology. 2011;29(12):1083-1089. http://dx.doi.org/10.1038/nbt.2060

237. Aggarwal S. Systematic review of non-interferon based regimens for chronic hepatitis C treatment. Value in Health. 2011;14(7):A267. http://dx.doi.org/10.1016/j.jval.2011.08.197

238. Aggarwal S. Trends in rate and cost of hospitalizations due to chronic kidney disease (CKD) in the united states. Value in Health. 2011;14(7). http://dx.doi.org/10.1016/j.jval.2011.08.549

239. Aggarwal S. Global health care reforms and pricing, access and health outcomes strategy. Value in Health. 2011;14(7). http://dx.doi.org/10.1016/j.jval.2011.08.654

240. Aggarwal S. Review of cost effectiveness models of high budget impact drugs. Value in Health. 2011;14(7):A361. http://dx.doi.org/10.1016/j.jval.2011.08.705

241. Aggarwal S. Novel drug reimbursement models: Lessons and implications from cancer drug access schemes. Value in Health. 2011;14(7):A361. http://dx.doi.org/10.1016/j.jval.2011.08.706

242. Aggarwal S. Impact of amnog on pharmaceutical pricing trends in Germany. Value in Health. 2011;14(7):A362. http://dx.doi.org/10.1016/j.jval.2011.08.712

243. Aggarwal S. Novel patient reported outcomes and data tool for chronic disease management (PROCDIM): Case in point prostate cancer. Value in Health. 2011;14(7). http://dx.doi.org/10.1016/j.jval.2011.08.1036

244. Aggarwal S. Systematic review of clinical efficacy and safety outcomes of anti-angiogenic therapies for metastatic colorectal cancer. Value in Health. 2011;14(7):A436. http://dx.doi.org/10.1016/j.jval.2011.08.1115

245. Aggarwal S. Budget impact model for rare cancer treatment: Case in point cutaneous T-cell lymphoma. Value in Health. 2011;14(7):A438. http://dx.doi.org/10.1016/j.jval.2011.08.1125

246. Aggarwal S. Cancer drug prices in the United States and the United Kingdom: Implications for pricing strategy and drug access. Value in Health. 2011;14(7):A466. http://dx.doi.org/10.1016/j.jval.2011.08.1275